- Home
- KAVL vs APTO Comparison
KAVL vs APTO Comparison
Compare KAVL & APTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- APTO
- Stock Information
- Founded
- KAVL 1998
- APTO 1986
- Country
- KAVL United States
- APTO Canada
- Employees
- KAVL N/A
- APTO N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KAVL Health Care
- APTO Health Care
- Exchange
- KAVL Nasdaq
- APTO Nasdaq
- Market Cap
- KAVL 11.4M
- APTO 13.2M
- IPO Year
- KAVL N/A
- APTO N/A
- Fundamental
- Price
- KAVL $0.94
- APTO $0.16
- Analyst Decision
- KAVL
- APTO Strong Buy
- Analyst Count
- KAVL 0
- APTO 3
- Target Price
- KAVL N/A
- APTO $4.33
- AVG Volume (30 Days)
- KAVL 379.3K
- APTO 17.4M
- Earning Date
- KAVL 02-10-2025
- APTO 03-25-2025
- Dividend Yield
- KAVL N/A
- APTO N/A
- EPS Growth
- KAVL N/A
- APTO N/A
- EPS
- KAVL N/A
- APTO N/A
- Revenue
- KAVL $6,886,665.00
- APTO N/A
- Revenue This Year
- KAVL N/A
- APTO N/A
- Revenue Next Year
- KAVL N/A
- APTO N/A
- P/E Ratio
- KAVL N/A
- APTO N/A
- Revenue Growth
- KAVL N/A
- APTO N/A
- 52 Week Low
- KAVL $0.58
- APTO $0.13
- 52 Week High
- KAVL $9.69
- APTO $1.94
- Technical
- Relative Strength Index (RSI)
- KAVL 38.29
- APTO 42.85
- Support Level
- KAVL $0.93
- APTO $0.13
- Resistance Level
- KAVL $1.49
- APTO $0.26
- Average True Range (ATR)
- KAVL 0.13
- APTO 0.02
- MACD
- KAVL -0.06
- APTO -0.00
- Stochastic Oscillator
- KAVL 3.27
- APTO 24.69
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.